Monoclonal Antibodies Produced for Alzheimer's Disease Blood Test

Monoclonal antibodies (mAbs) were successfully produced for a diagnostic blood test for Alzheimer's disease (AD).

A simple, easy to use diagnostic blood test for AD is ready for clinical testing. Human sample testing has begun and will run over the next few months.

biOasis Technologies Inc. (Vancouver, BC, Canada) announced the completion of a project intended to produce proprietary monoclonal antibodies (mAbs) for its Cognitest blood test for Alzheimer's disease. Working in collaboration with Fleet Bioprocessing (Hartley Witney, United Kingdom), and OxFabs (Oxford, United Kingdom), the company generated numerous antibodies and assessed their performance in prototype assays. The best performing mAbs were selected for use within production prototypes.

"The selection of monoclonal antibodies is an important step in the Cognitest program," said Rob Hutchison, biOasis Chairman and CEO. "Our strategy is to create new intellectual property and ensure ownership of key components within our products. We are now working to assess Cognitest using human samples from North America and Europe. Our intention is to expand the validation studies by collaborating with clinical thought leaders interested in an easy-to-use quantitative test for Alzheimer's disease. The ability to diagnose Alzheimer's has always been known to be very difficult due to the fact that many forms of dementia mimic Alzheimer's and as such a simple quick blood test would provide physicians with a tool to combat this dreadful disease."

Current initiatives within the Cognitest program include product and method development, validation using human samples, and regulatory approval in Europe. To enable faster adoption and greater use of Cognitest the company intends to out-license it to leading in vitro diagnostic companies.

In addition, biOasis is developing a proprietary carrier for the transport of therapeutic and imaging agents across the blood brain barrier--the Transcend program. Current initiatives within the Transcend program include production of materials for preclinical studies and conjugation to a range of small molecule and biologic therapeutics. To address the clinical need to transport drugs across the blood-brain barrier biOasis intends to license multiple candidate compounds from the Transcend program to corporate partners.

Related Links:
biOasis Technologies Inc.
Fleet Bioprocessing
OxFabs